← FDA DRUG APPROVALS

FDA ANDA · ANDA209460

ITRACONAZOLE

Sponsor: TORRENT

APPLICATION
ANDA209460
TYPE
ANDA
ORIGINAL APPROVAL
2018-08-24
LATEST ACTION
2024-05-30
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

ITRACONAZOLEPrescription
ITRACONAZOLE 100MG · CAPSULE · ORAL

Approval history

2024-05-30Labeling · Supplement 7 · standardAP
2024-01-29Labeling · Supplement 5 · standardAP
2023-05-26Labeling · Supplement 4 · standardAP
2019-10-21Labeling · Supplement 2 · standardAP
2018-08-24UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →